866323-86-6 Usage
Description
2-Propenoic acid, 3-[3-[(phenylamino)sulfonyl]phenyl]-, Methyl ester, (2E)-, commonly known as the methyl ester of 3-(3-aminosulfonylphenyl)acrylic acid, is a chemical compound with potential medicinal properties. It is primarily used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceuticals and as a raw material for the production of other organic compounds. 2-Propenoic acid, 3-[3-[(phenylaMino)sulfonyl]phenyl]-, Methyl ester, (2E)is also being studied for its anti-inflammatory and anti-cancer properties, making it a promising candidate for further research and development.
Uses
Used in Pharmaceutical Industry:
2-Propenoic acid, 3-[3-[(phenylamino)sulfonyl]phenyl]-, Methyl ester, (2E)is used as an intermediate in the synthesis of various pharmaceuticals for its potential medicinal properties.
Used in Research and Development:
2-Propenoic acid, 3-[3-[(phenylamino)sulfonyl]phenyl]-, Methyl ester, (2E)is used in research and development for its potential anti-inflammatory and anti-cancer properties, making it a promising candidate for further studies and applications in the medical field.
Used in Organic Compound Production:
2-Propenoic acid, 3-[3-[(phenylamino)sulfonyl]phenyl]-, Methyl ester, (2E)is used as a raw material for the production of other organic compounds, contributing to the development of new chemical entities and materials.
It is important to handle this chemical with care, as it can pose health risks if not used properly. Proper safety measures and guidelines should be followed during its synthesis, storage, and application to ensure the safety of individuals and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 866323-86-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,6,3,2 and 3 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 866323-86:
(8*8)+(7*6)+(6*6)+(5*3)+(4*2)+(3*3)+(2*8)+(1*6)=196
196 % 10 = 6
So 866323-86-6 is a valid CAS Registry Number.
866323-86-6Relevant articles and documents
COMPOUNDS AND METHODS FOR TREATING CANCER
-
, (2020/12/19)
Substituted cinnamamide compounds and analogs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or ameliorate cancer are provided.
POLYMORPHIC FORMS OF BELINOSTAT AND PROCESSES FOR PREPARATION THEREOF
-
, (2018/02/28)
The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.
Novel sulfonamide derivatives as inhibitors of histone deacetylase
Finn, Paul W.,Bandara, Morwena,Butcher, Chris,Finn, Angela,Hollinshead, Ruth,Khan, Nagma,Law, Norman,Murthy, Sreenivasa,Romero, Rosario,Watkins, Clare,Andrianov, Victor,Bokaldere, Rasma M.,Dikovska, Klara,Gailite, Vija,Loza, Einars,Piskunova, Irina,Starchenkov, Igor,Vorona, Maxim,Kalvinsh, Ivars
, p. 1630 - 1657 (2007/10/03)
Inhibition of the enzyme histone deacetylase (HDAC) is emerging as a novel approach to the treatment of cancer. A series of novel sulfonamide derivatives were synthesized and evaluated for their ability to inhibit human HDAC. Compounds were identified which are potent enzyme inhibitors, with IC 50 values in the low nanomolar range against enzyme obtained from HeLa cell extracts, and with antiproliferative effects in cell culture. Extensive characterization of the structure - activity relationships of this series identified key requirements for activity. These include the direction of the sulfonamide bond and substitution patterns on the central phenyl ring. The alkyl spacer between the aromatic head group and the sulfonamide functionality also influenced the HDAC inhibitory activity. One of these compounds, m11.1, also designated PXD101, has entered clinical trials for solid tumors and haematological malignancies.
